THERAPY DOSSIER · th-a57c43c40ccb

Fraxinus xanthoxyloides methanolic leaf extract

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30058538 ↗2018Reported benefit

Ameliorating role of methanolic leaves extract of Fraxinus xanthoxyloides against CCl4-challanged nephrotoxicity in rats.

RatChemical/toxinSprague-DawleyMale

Model: Carbon tetrachloride-induced nephrotoxicity

Carbon tetrachloride impaired renal function, depleted antioxidant enzymes and increased lipid peroxidation and DNA damage. Co-treatment with the leaf extract, like silymarin, restored the measured parameters towards control values.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…